Scopolamine fails to diminish chronic haloperidol-induced purposeless chewing in rats

Psychopharmacology

Volumn 153, Issue 2, 2001, Pages 191-195

  Sakai, K ^a   Gao, X M ^a   Tamminga, C A ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Rat oral dyskinesia; Scopolamine; Tardive dyskinesia; Vacuous chewing movement; VCM

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; PLACEBO; SCOPOLAMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SIMULATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; TARDIVE DYSKINESIA; TREATMENT FAILURE;

ANIMALS; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE; STEREOTYPED BEHAVIOR;

EID: 0035144132     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000570     Document Type: Article

References (37)

1. Effects of prenatal exposure to a mild chronic variable stress on body weight, preweaning mortality and rat behavior
2. Pharmacological characterization of tardive dyskinesia
3. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal
4. The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements
5. Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48 hour time course
6. Ionotropic glutamate receptors and NMDA subunit expression in subregions of human hippocampus: Effects of schizophrenia
7. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia
8. Persistent vacuous chewing in rats following neuroleptic treatment: Relationship to dopaminergic and cholinergic function
9. Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat
10. 5-Hydroxytryptamine-moduline: A novel endogenous peptide involved in the control of anxiety
11. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration
12. Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
13. Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: Evaluation of a revised animal model of tardive dyskinesia
14. Behavioral consequences of long-term treatment with neuroleptic drugs
15. Integrating incidence and prevalence of tardive dyskinesia
16. Effect of cholinergic and anticholinergic agents on tardive dyskinesia
17. Reversibility of tardive dyskinesia following neuroleptic withdrawal
18. 1 mechanisms in the antiparkinsonian effects of SKF 82958 (APB): Studies of tremulous jaw movements in rats
19. Animal models of depression
20. Neuroleptic-induced oral dyskinesias: Effects of progabide and lack of correlation with regional changes in glutamic acid decarboxylase and choline acetyltransferase activities
21. Individual differences in behavioral reactivity: Correlation with stress-induced norepinephrine efflux in the hippocampus of Sprague-Dawley rats
22. 2 dopamine receptor function and the emergence of repetitive jaw movements
23. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat
24. Cholinergic modulation of oral activity in drug-naive and chronic haloperidol-treated rats
25. Vacuous jaw movements induced by sub-chronic administration of haloperidol: Interactions with scopolamine
26. Cholinergic influences in tardive dyskinesia
27. Improvement in tardive dyskinesia after muscimol therapy
28. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: A study in three rat strains
29. Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic functions of catecholamines
30. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment
31. Clonazepam treatment of tardive dyskinesia: A practical GABAmimetic strategy
32. Behavioral assessment of atypical antipsychotics in rats: Studies of the effects of olanzapine (Zyprexa)
33. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and electroconvulsive therapy
34. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
35. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment
36. Animal models of depression and schizophrenia
37. Treatment of dyskinetic syndromes